(JREE) JPMorgan s (Ireland) ICAV - - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Etf • ISIN: IE00BF4G7183 • Europe Large-Cap Blend Equity
JREE: European, Stocks, Index, Fund, Equity
Here’s what you need to know about the JPMorgan ETFs (Ireland) ICAV - Europe Research Enhanced Index Equity UCITS ETF - EUR (acc), listed on XETRA under the ticker JREE. This fund is designed for investors seeking exposure to large-cap European equities with a blend of growth and value characteristics. It’s part of JPMorgan’s lineup of UCITS-compliant ETFs, which are structured to meet the regulatory and transparency standards demanded by European investors.
The ETF tracks the Morningstar DM Eur TME NR EUR index, which focuses on developed market equities in Europe. The fund employs a research-enhanced index strategy, meaning it uses quantitative models to identify and weight securities that are expected to outperform the broader market. This approach aims to deliver returns that are incrementally better than traditional market-cap-weighted indices while maintaining a risk profile similar to the benchmark.
As of the latest data, the fund has an AUM of 1.218.35M EUR, which indicates it has reached a scale that allows for efficient trading and tight tracking error. The ETF is structured as an accumulation share class (acc), meaning it reinvests dividends and other distributions, which can be advantageous for long-term growth investors. It’s listed on XETRA, making it accessible to European investors who prefer trading in euros.
For fund managers and institutional investors, this ETF offers a way to gain diversified exposure to European large-cap equities with the potential for enhanced returns through JPMorgan’s research-driven approach. It’s suitable for portfolios seeking a core equity allocation in Europe or as a complement to actively managed strategies. The UCITS wrapper ensures compliance with European regulatory standards, making it a viable option for both retail and institutional investors.
Additional Sources for JREE ETF
JREE ETF Overview
Market Cap in USD | 1,280m |
Category | Europe Large-Cap Blend Equity |
IPO / Inception | 2020-06-30 |
JREE ETF Ratings
Growth 5y | 58.0% |
Fundamental | - |
Dividend | 0.0% |
Rel. Strength Industry | 4.41 |
Analysts | - |
Fair Price Momentum | 42.76 EUR |
Fair Price DCF | - |
JREE Dividends
No Dividends PaidJREE Growth Ratios
Growth Correlation 3m | 79.7% |
Growth Correlation 12m | 36.3% |
Growth Correlation 5y | 92.2% |
CAGR 5y | 9.07% |
CAGR/Max DD 5y | 0.28 |
Sharpe Ratio 12m | 0.83 |
Alpha | 2.30 |
Beta | 0.51 |
Volatility | 9.60% |
Current Volume | 12.3k |
Average Volume 20d | 16k |
As of February 22, 2025, the stock is trading at EUR 45.78 with a total of 12,314 shares traded.
Over the past week, the price has changed by +0.00%, over one month by +4.87%, over three months by +9.76% and over the past year by +13.40%.
Partly, yes. Based on ValueRay Analyses, JPMorgan s (Ireland) ICAV - (XETRA:JREE) is currently (February 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 57.99 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of JREE as of February 2025 is 42.76. This means that JREE is currently overvalued and has a potential downside of -6.6%.
JPMorgan s (Ireland) ICAV - has no consensus analysts rating.
According to ValueRays Forecast Model, JREE JPMorgan s (Ireland) ICAV - will be worth about 49.3 in February 2026. The stock is currently trading at 45.78. This means that the stock has a potential upside of +7.71%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 49.3 | 7.7% |